Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8+ T cells

Vaccine

Volumn 31, Issue 17, 2013, Pages 2110-2118

  Muraoka, Daisuke ^a,b   Nishikawa, Hiroyoshi ^a,c   Noguchi, Takuro ^a,d   Wang, Linan ^a   Harada, Naozumi ^a,b   Sato, Eiichi ^e   Luescher, Immanuel ^f   Nakayama, Eiichi ^g   Kato, Takuma ^a   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ImmunoFrontier Inc   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

Author keywords

Animal model; Cacer testis antigens; Cancer vaccine; CD8+ T cells; Immune responses; Translational research

Indexed keywords

EPITOPE; GAMMA INTERFERON; MELANOMA ANTIGEN 4; NY ESO 1 ANTIGEN; TETRAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE GUN IMMUNIZATION; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CANCER VACCINES; CROSS-PRIMING; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TESTIS; TIME FACTORS;

EID: 84875869939     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.056     Document Type: Article

References (22)

1. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y-T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32.
2. Boon T., Coulie P.G., Van den Eynde B.J., Human van der Bruggen P. T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
3. Gnjatic S., Nishikawa H., Jungbluth A.A., Gure A.O., Ritter G., Jager E., et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006, 95:1-30.
4. Belardelli F., Ferrantini M., Parmiani G., Schlom J., Garaci E. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?. Cancer Res 2004, 64(18):6827-6830.
5. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10(9):909-915.
6. Chen Y-T., Scanlan M.J., Sahin U., Tureci O., Gure A.O., Tsang S., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997, 94(5):1914-1918.
7. De Plaen E., De Backer O., Arnaud D., Bonjean B., Chomez P., Martelange V., et al. A new family of mouse genes homologous to the human MAGE genes. Genomics 1999, 55(2):176-184.
8. Duffour M.T., Chaux P., Lurquin C., Cornelis G., Boon T., van der Bruggen P. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 1999, 29(10):3329-3337.
9. Miyahara Y., Naota H., Wang L., Hiasa A., Goto M., Watanabe M., et al. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res 2005, 11(15):5581-5589.
10. Nishikawa H., Tanida K., Ikeda H., Sakakura M., Miyahara Y., Aota T., et al. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity. Proc Natl Acad Sci USA 2001, 98(25):14571-14576.
11. Nishikawa H., Sato E., Briones G., Chen L.M., Matsuo M., Nagata Y., et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006, 116(7):1946-1954.
12. Griswold D.P., Corbett T.H. A colon tumor model for anticancer agent evaluation. Cancer 1975, 36(6 Suppl):2441-2444.
13. + T cells. J Immunol 2010, 185(6):3768-3776.
14. Jager E., Stockert E., Zidianakis Z., Chen Y-T., Karbach J., Jager D., et al. Humoral immune responses of cancer patients against Cancer-Testis antigen NY-ESO-1: Correlation with clinical events. Int J Cancer 1999, 84(5):506-510.
15. Nishikawa H., Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010, 127(4):759-767.
16. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10(9):942-949.
17. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102(51):18538-18543.
18. Noguchi T., Kato T., Wang L.N., Maeda Y., Ikeda H., Sato E., et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res 2012, 72(7):1672-1682.
19. Gotter J., Brors B., Hergenhahn M., Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 2004, 199(2):155-166.
20. Danke N.A., Koelle D.M., Yee C., Beheray S., Kwok W.W. Autoreactive T cells in healthy individuals. J Immunol 2004, 172(10):5967-5972.
21. + helper T cell responses in cancer patients. Blood 2005, 106:1008-1011.
22. + T cells following peptide vaccination. J Immunol 2006, 176(10):6340-6346.